Eton Pharmaceuticals, Inc 8-K, filed Mar 18, 2020
Eton Pharmaceuticals, Inc. (ETON)
About this 8-K
Eton Pharmaceuticals, Inc filed this 8-K on March 18, 2020, reporting on events of March 17, 2020.
Items reported
- Item 8.01: Other events
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENTREPORT
Pursuantto Section 13 or 15(d) of the Securities Exchange Act of 1934
March17, 2020
Dateof Report (Date of earliest event reported)
ETONPHARMACEUTICALS, INC.
(Exactname of registrant as specified in its charter)
| Delaware | 001-38738 | 37-1858472 |
|---|---|---|
| (State of | (Commission | (I.R.S. Employer |
| incorporation) | **** File Number) | Identification Number) |
21925W. Field Parkway, Suite 235
DeerPark, Illinois 60010-7208
(Addressof principal executive offices) (Zip code)
(847)787-7361
(Registrant’stelephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications<br> pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting material<br> pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | ETON | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item8.01 Other Events.
On March 17, 2020, as expected, Eton’s partner received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) related to the New Drug Application for ET-105. The FDA’s letter primarily cited the Dosing and Administration related topics that Eton had outlined in its press release on February 19, 2020. The letter also contained minor questions and clarifications related to the Product Quality section of the review. Eton continues to believe that all issues in the letter can be resolved and addressed in a resubmission during the second or third quarter of this year.
| 2 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 18, 2020 | By: | /s/ W. Wilson Troutman |
|---|---|---|
| W. Wilson Troutman | ||
| Chief Financial Officer and Secretary | ||
| (Principal Financial Officer) |
| 3 |
| --- |